Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: A retrospective cohort study

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 2010-2021

  Nurko, Saul ^a   Spirko, Rita ^a   Law, Amy ^b   Dennis, Vincent W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

anemia; chronic kidney disease; darbe poetin; erythropoietin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

AGED; ANEMIA; CHRONIC DISEASE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; RETROSPECTIVE STUDIES;

EID: 36749102022     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.012     Document Type: Article

References (32)

1. Nurko S. Anemia in chronic kidney disease: Causes, diagnosis, treatment. Cleve ClinJ Med. 73 (2006) 289-297
2. McClellan W., Aronoff S., Bolton W., et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20 (2004) 1501-1510
3. Bishop M. Sick and tired. NursStand 20 (2005) 26-27
4. Besarab A., and Aslam M. Should the hematocrit (hemoglobin) be normalized in pre-ESRD or dialysis patients?. Yes! BloodPurif 19 (2001) 168-174
5. McCullough P., and Lepor N. Piecing together the evidence on anemia: The link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 6(Suppl 3) (2005) S4-S12
6. Rossert J., Froissart M., and Jacquot C. Anemia management and chronic renal failure progression. Kidney Int Suppl 99 (2005) $76-$81
7. Dean B., Dylan M., Gano A., et al. Eryth ropoiesis-stim ulating protein therapy and the decline of renal function: A retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 21 (2005) 981-987
8. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations For anemia in chronic kidney disease. AmJ Kidney Dis 47 Suppl 3 (2006) S11-S145
9. Jungers P., Choukroun G., Oualim Z., et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16 (2001) 307-312
10. Walker A., Schneider G., Yeaw J., et al. Anemia as a predictor of cardiovascular events in patients with ele- vated serum creatinine. J Am Soc Nephrol 17 (2006) 2293-2298
11. Kovesdy C., Trivedi B., Kalantar- Zadeh K., and Anderson J. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 69 (2006) 560-564
12. Drueke T., Locatelli F., Clyne N., et al., for the CREATE Investigators. Nor- malization of hemoglobin level in patients with chronic kidney disease and anemia. NEnglJMed 355 (2006) 2071-2084
13. Singh A., Szczech L., Tang K., et al., for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng/ J Med 355 (2006) 2085-2098
14. National Kidney Foundation. KDOQI clinical practice guideline and clini- cal practice recommendations for anemia in chronic kidney disease: 2007 Update of hemoglobin target. AmJ Kidney Dis 50 (2007) 471-530
15. National Kidney Foundation. IV. NKF-K/DOQI clinical practice guide- lines For anemia of chronic kidney disease. Am J Kidney Dis 38 (2001) 442 Update 2000 published correction appears in
16. Am J Kidney Dis 37 Suppl 1 (2001) $182-$238
17. Eschbach J., Kelly M., Haley N., et al. Treatment of the anemia of progressive renal failure with recom- binant human erythropoietin. N Engl J Med 321 (1989) 158-163
18. Locatelli F., Olivares J., Walker R., et al., for the European/Australian NESP 980202 Study Group. Novel eryth- ropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 60 (2001) 741-747
19. Toto R., Pichette V., Navarro J., et al. Darbepoetin alfa effectively treats anemia in patients with chronic kid- ney disease with de novo every-other- week administration. Am J Nephrol 24 (2004) 453-460
20. Provenzano R., Bhaduri S., Singh A., and for the PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the ane- mia of chronic kidney disease: The PROMPT study. Clin Nephrol 64 (2005) 113-123
21. Ling B., Walczyk M., Agarwal A., et al. Darbepoetin alfa administered once monthly maintains hemoglobin con- centrations in patients with chronic kidney disease. Clin Nepkrol 63 (2005) 327-334
22. Germain M., Ram C., Bhaduri S., et al. Extended epoetin alfa dosing in chronic kidney disease patients: A retrospective review. Nephrol Dial Transplant 20 (2005) 2146-2152
23. Fishbane S. Recombinant human eryth- ropoietin: Has treatment reached its full potential?. Semin Dial 19 (2006) 1-4
24. Bems J., and Fishbane S. Hemoglobin variability: Random fluctuation, epiphe- nomenon, or phenomenon?. Semin Dial 19 (2006) 257-259
25. Besarab A., Bolton W., Browne J., et al. The effects of normal as com- pared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoe- tin. N Engl J Med 339 (1998) 584-590
26. Robinson D., and Easthope S. Darbe- poetin alfa: Its use in anemia asso- ciated with chronic kidney disease. BioDrugs 19 (2005) 327-343
27. US Food and Drug Administration. Information for healthcare professionals: Erythropoiesis stimulating agents (ESA) (Aranesp [darbepoetin], Epogen [epoetin alfa], and Procrit [epoetin alfa]. Available at:. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2OO7HCP.htm" Accessed April 10, 2007
28. Fishbane S., and Berns J. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoiein. Kidney Int. 68 (2005) 1337-1343
29. Medical Officer Clinical Review. STN103951. Darbepoetin alfa. Amgen Inc. Available at:. http://www.fda.gov/CDER/biologics/review/ARANESP_MedOfficer_Review.pdf Accessed September 17, 2007
30. Jadoul M., Vanrenterghem Y., Foret M., et al. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19 (2004) 898-903
31. Rice L., Alfrey C., Driscoll T., et al. Neocytolysis contributes to the ane- mia of'renal disease. AmJ Kidney Dis 33 (1999) 59-62
32. Beshara S., Barany P., Gutierrez A., Wikstrom B., and for the Swedish Inves- tigators Group. Varying intervals of- subcutaneous epoetin alfa in hemo- dialysis patients. J Nephrol 17 (2004) 525-530